AzTrials
AzTrials

Fuchs Endothelial Corneal DystrophyNCT07731945

Postoperative CCT in FECD vs. Non-FECD

An observational study of Fuchs Endothelial Corneal Dystrophy and Cataract (Post-operative Cataract Surgery Follow-up), run by Vienna Hospital Association.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

This single-centre, prospective, controlled, non-interventional observational clinical study aims to characterize early postoperative corneal thickness behaviour after routine phacoemulsification cataract surgery in eyes with Fuchs endothelial corneal dystrophy (FECD) compared with non-FECD controls, using exclusively… Read more about this study

Who is it for?
Ages 50 years and olderHealthy volunteers can take part
How many people
98 participants
Where
No sites listed yet
Study dates
20 Jul 2026to Aug 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: This study will include approximately 98 eyes scheduled for routine phacoemulsification cataract surgery at the Augenabteilung, Klinik Hietzing, Wiener Gesundheitsverbund (Vienna, Austria). The indication to perform cataract surgery will have been made prior to and independently of study participation. Participants will be enrolled from the routine cataract surgery population and allocated to one of two cohorts based on the presence or absence of Fuchs endothelial corneal dystrophy (FECD) as determined during standard preoperative assessment.

Who may be able to join

  • Signed written informed consent for participation and for use of routine clinical data in pseudonymised form.
  • Age ≥50 years at the time of cataract surgery.
  • Scheduled cataract surgery (unilateral/bilateral cataract).
  • No evidence of other ophthalmic diseases (e.g. macular pathology)
  • Cohort-specific inclusion:
  • FECD cohort: Clinical diagnosis of FECD based on slit-lamp findings, graded accord-ing to Krachmer et al. (1978) as documented in routine care.
  • Control cohort: No clinical evidence of corneal endothelial disease at baseline (no signs consistent with FECD or other endothelial pathology) as documented in routine care.

Who cannot join

  • Corneal scars
  • Pseudoexfoliation (PEX) syndrome
  • Glaucoma
  • Uveitis
  • Diabetic retinopathy
  • Other relevant ophthalmic disorders (e.g. retinal degeneration, macular or corneal pa-thologies)
Show all 10Show fewer
  • Previous intraocular surgery (including laser procedures)
  • Ocular trauma (within the past 6 months)
  • Pregnancy (if applicable, pregnancy must be excluded by a β-hCG test)
  • CCT > 625μm

About this study

Official title: Central Corneal Thickness After Cataract Surgery in Eyes With Fuchs Endothelial Corneal Dystrophy (FECD) Compared With Non-FECD Eyes: A Prospective, Controlled, Non-interventional Observational Clinical Study

This single-centre, prospective, controlled, non-interventional observational clinical study aims to characterize early postoperative corneal thickness behaviour after routine phacoemulsification cataract surgery in eyes with Fuchs endothelial corneal dystrophy (FECD) compared with non-FECD controls, using exclusively standard-of-care perioperative assessments. To compare central corneal thickness (CCT) six weeks postoperatively between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT.

All participants undergo routine phacoemulsification cataract surgery and routine perioperative assessments. Data are collected from the standard-of-care documentation at the following time points:

Read more
  1. Preoperative baseline visit (routine cataract work-up)
  2. Study specific postoperative follow-up at approximately 6 weeks. Each participant will attend a study-specific follow-up visit at 6 weeks postoperatively and contributes study-specific follow-up data up to this time point.

The routine clinical parameters assessed (as available per standard practice) include:

(A) Medical history / baseline characteristics and documentation of ocular/systemic comorbidities and topical medication.

(B) Best-corrected visual acuity (BCVA) (logMAR).

(C) Intraocular pressure (IOP) measured by Goldmann applanation tonometry (GAT).

(D) Slit-lamp examination (including assessment of corneal clarity/edema and anterior segment findings) with fundoscopy as routinely documented.

(E) Central corneal thickness (CCT) measurement using routine clinical devices. All measurements will be performed at a consistent time of day for each patient.

(F) Anterior segment optical coherence tomography (AS-OCT) using Casia2.

(G) Anterior segment Scheimpflug tomography (Pentacam Oculus AXL).

(H) Endothelial cell assessment or Endothelial Cell Count (ECC) examined with NIDEK® CEM-530 Specular Microscope:

  • Cell Density (CD) or Cell Count. Expressed as Cells/mm²
  • Coefficient of Variation (CV), represents the degree of variation in cell size (Polymegethism)
  • Percentage (%) of six-sided (hexagon) cells (HEX)
  • Standard Deviation (SD) of the average cell area.
Read the detailed description

This is a single-centre, prospective, controlled, non-interventional observational clinical study conducted at the Augenabteilung, Klinik Hietzing, Wiener Gesundheitsverbund, Vienna, Austria.

Fuchs endothelial corneal dystrophy (FECD) is a progressive disorder of the corneal endothelium characterized clinically by central guttae and a gradual loss of endothelial barrier and pump function, ultimately leading to corneal edema, increased corneal thickness, and visual impairment. In FECD, thickening is primarily a consequence of stromal hydration (deturgescence failure), and corneal edema can be present even when it is not yet obvious on slit-lamp examination ("subclinical edema"), which complicates clinical staging and risk estimation in routine practice.

Because cataract prevalence increases with age, cataract and FECD frequently coexist, and cataract surgery planning in FECD must account for the reduced endothelial reserve. Phacoemulsification - although highly standardized and effective - exerts mechanical, ultrasonic, and fluidic stress on the endothelium and can cause postoperative endothelial cell loss even in otherwise healthy eyes. Large, randomized data have shown that modern cataract surgery can measurably affect the corneal endothelium and that the magnitude of endothelial impact depends on patient- and surgery-related factors. Clinically, inadequate endothelial pump function is a key mechanism underlying postoperative corneal edema after cataract surgery, making endothelial vulnerability a central safety consideration in FECD eyes.

Central corneal thickness (CCT) is a routinely available, quantitative parameter that reflects corneal hydration status and is commonly used in clinical decision making in FECD, because the central cornea thickens as edema develops. In FECD specifically, clinicians frequently incorporate CCT into perioperative assessment; however, isolated CCT values have limitations because normal corneas can occasionally be thick and because "pre-edematous" baseline thickness varies across individuals. As a result, thresholds (e.g., around 640 µm) have been proposed as practical indicators of clinically relevant edema in FECD, but the overlap between normal variation and early/subclinical disease underscores the need to interpret CCT in context and - when possible - relative to baseline.

In the postoperative setting, transient corneal swelling (reflected by increased CCT) is a well-recognized phenomenon after phacoemulsification, and it is mechanistically linked to surgical endothelial stress. Studies evaluating postoperative corneal swelling after phacoemulsification show that CCT can increase early after surgery and then trend back toward baseline in uncomplicated cases, whereas persistent edema is more likely when endothelial reserve is compromised. Moreover, postoperative corneal swelling has been shown to correlate with endothelial cell loss after phacoemulsification, supporting the use of CCT as a clinically meaningful, non-invasive outcome reflecting endothelial "load" in the early postoperative period.

From a methodological perspective, comparing postoperative CCT between FECD and non-FECD eyes requires careful handling of baseline variability, because corneal thickness differs substantially between individuals and baseline imbalance can bias or obscure group differences if not appropriately addressed. In controlled clinical studies with baseline and follow-up measurements, inclusion of the baseline value as a covariate in an analysis of covariance (ANCOVA) framework is widely recommended because it conditions the comparison on baseline, improves precision, and avoids the bias that can arise with alternative approaches (e.g., analysing change scores without proper adjustment), particularly when baseline and follow-up are correlated. This is directly aligned with the statistical objective of estimating the group effect on postoperative CCT while accounting for preoperative thickness heterogeneity.

Against this background, the present study is designed as a prospective, controlled, non-interventional observational clinical investigation to quantify early postoperative CCT outcomes after routine phacoemulsification in FECD compared with non-FECD controls. The primary objective is to compare CCT at 6 weeks postoperatively between groups while adjusting for baseline preoperative CCT using ANCOVA, thereby providing an interpretable, baseline-conditioned estimate of the association between FECD status and postoperative corneal thickness under real-world clinical conditions. Secondary objectives include characterizing the magnitude of postoperative CCT change relative to baseline and exploring whether baseline corneal/lens characteristics (including FECD severity graded by commonly used clinical grading frameworks) are associated with postoperative CCT trajectories. By relying exclusively on standard-of-care perioperative assessments, the study aims to generate clinically applicable evidence to support perioperative risk stratification and patient counselling in FECD patients undergoing cataract surgery.

Keywords
Postoperative CCT, Fuchs Endothelial Corneal Dystrophy, FECD, CCT in FECD, Cataract Surgery FECD
Medical subject headings
Fuchs' Endothelial Dystrophy, Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07731945
Study groupRoleWhat they receive
Patients with Fuchs endothelial corneal dystrophy (FECD)Patients with Fuchs endothelial corneal dystrophy (FECD). Clinical diagnosis of FECD based on slit-lamp findings, graded according to Krachmer et al. (1978).
Non-FECDPatients without Fuchs endothelial corneal dystrophy (FECD). Control cohort: No clinical evidence of corneal endothelial disease at baseline (no signs consistent with FECD or other endothelial pathology)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Central corneal thickness (CCT, µm) six weeks after routine phacoemulsification cataract surgery, compared between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT

    The primary endpoint of this study is central corneal thickness (CCT, µm) six weeks after routine phacoemulsification cataract surgery, compared between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT.

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jul 2026
  2. Study start20 Jul 2026 (estimated)
  3. Primary completionJul 2027 (estimated)
  4. Study completionAug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
98 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07731945
Sponsor's protocol ID
MA15-EK26-046-0426
Status last verified
Aug 2026
First submitted
22 Jul 2026
Last updated
10 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Fuchs Endothelial Corneal Dystrophy and Cataract (Post-operative Cataract Surgery Follow-up), run by Vienna Hospital Association.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Central corneal thickness (CCT, µm) six weeks after routine phacoemulsification cataract surgery, compared between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in